BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27481359)

  • 1. MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound.
    Airan RD; Foss CA; Ellens NP; Wang Y; Mease RC; Farahani K; Pomper MG
    Mol Imaging Biol; 2017 Feb; 19(1):24-30. PubMed ID: 27481359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study.
    Harsini S; Saprunoff H; Alden T; Mohammadi B; Wilson D; Bénard F
    J Nucl Med; 2021 Jan; 62(1):81-87. PubMed ID: 32385167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective Comparison of PET Imaging with PSMA-Targeted
    Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
    J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
    Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
    J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
    Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
    Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
    Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
    Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 68Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization.
    Derlin T; Thiele J; Weiberg D; Thackeray JT; Püschel K; Wester HJ; Aguirre Dávila L; Larena-Avellaneda A; Daum G; Bengel FM; Schumacher U
    Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2213-2219. PubMed ID: 27609368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents.
    Endepols H; Morgenroth A; Zlatopolskiy BD; Krapf P; Zischler J; Richarz R; Muñoz Vásquez S; Neumaier B; Mottaghy FM
    BMC Cancer; 2019 Jun; 19(1):633. PubMed ID: 31242896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas.
    Salas Fragomeni RA; Menke JR; Holdhoff M; Ferrigno C; Laterra JJ; Solnes LB; Javadi MS; Szabo Z; Pomper MG; Rowe SP
    Clin Nucl Med; 2017 Oct; 42(10):e433-e435. PubMed ID: 28737579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
    Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
    J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
    Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.
    Chen Y; Lisok A; Chatterjee S; Wharram B; Pullambhatla M; Wang Y; Sgouros G; Mease RC; Pomper MG
    Bioconjug Chem; 2016 Jul; 27(7):1655-62. PubMed ID: 27270097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
    Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
    Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Study on
    Rousseau E; Wilson D; Lacroix-Poisson F; Krauze A; Chi K; Gleave M; McKenzie M; Tyldesley S; Goldenberg SL; Bénard F
    J Nucl Med; 2019 Nov; 60(11):1587-1593. PubMed ID: 30979820
    [No Abstract]   [Full Text] [Related]  

  • 17. Intraindividual Comparison of
    Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
    J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplified Methods for Quantification of
    Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
    J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
    Szabo Z; Mena E; Rowe SP; Plyku D; Nidal R; Eisenberger MA; Antonarakis ES; Fan H; Dannals RF; Chen Y; Mease RC; Vranesic M; Bhatnagar A; Sgouros G; Cho SY; Pomper MG
    Mol Imaging Biol; 2015 Aug; 17(4):565-74. PubMed ID: 25896814
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.